Multi‐biomarker panels and risk assessment models, such as the Risk of Ovarian Malignancy Algorithm (ROMA), which integrates CA‐125 and HE4, have demonstrated improved specificity in ovarian cancer diagnosis, particularly in distinguishing malignant tumors from benign ovarian cancer [20, 21]. This evidence concerns the gene WFDC2 and cancer.